Risk Assessment in Patients With Polycythemia Vera (PV)

Opinion
Video

Joe Scandura, MD, PhD, reviews how he approaches risk assessment in patients with polycythemia vera and how risk score helps to determine treatment.

Related Videos
A panel of 4 experts on bladder cancer seated at a long table
A panel of 4 experts on bladder cancer seated at a long table
Nicole Lamanna, MD, a hematologist-oncologist
Joseph P. McGuirk, DO, an expert on lymphoma
Joseph P. McGuirk, DO, an expert on lymphoma
Experts on endometrial cancer
Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, experts on lung cancer
Experts on endometrial cancer
Related Content
John Mascarenhas, MD

Pelabresib Plus Ruxolitinib Improves Spleen Volume Reduction in JAK Inhibitor-Naive Myelofibrosis

November 21st 2023
Article
Courtney D. DiNardo, MD, MSCE

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

November 20th 2023
Podcast
Gaby Hobbs, MD

Increased Understanding of the Mechanisms of Myelofibrosis Helps Usher in New Treatments and Novel Agents

November 16th 2023
Article
FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

September 19th 2022
Podcast
Andrew T. Kuykendall, MD, of Moffitt Cancer Center

FDA Approval of Momelotinib May Establish New SOC for Myelofibrosis With Anemia

November 2nd 2023
Article
FDA

FDA Approves Ivosidenib for Relapsed/Refractory IDH1-Mutant MDS

October 24th 2023
Article